Tradestie Institutional Equity Comparison Engine

COCP vs KZR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KZR Overall Edge

KZR Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Kezar Life Sciences, Inc. Common Stock (KZR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus KZR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against KZR sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
COCP N/M vs KZR N/M Fwd P/E
Growth & Margin Winner KZR
Op Margin -3063.6% vs 0.0% ยท YoY +26.9% vs +0.0%
Momentum & Technical Winner KZR
1Y -3.0% vs +78.7% ยท 52W Pos 19% vs 94%
Options & Structure Winner KZR
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (9th %ile IV)
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
1M Return -2.01%
1Y Return -2.96%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
KZR NASDAQ
Kezar Life Sciences, Inc. Common Stock
Pharmaceutical Preparations
$7.29
-0.95% 1D
Market Cap $54.4M
1M Return -0.82%
1Y Return +78.68%
Forward P/E N/M
Unified AI Score
60.1 / 100 BUY
Tech 40.0 Fund 51.0 Flow 56.0 Mom 58.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: COCP -2.96% KZR +78.68% Spread: +21.27 pp (COCP Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
COCP TTM Op. Margin: -3063.6% KZR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on COCP vs KZR. Trailing 12-month operating profitability (COCP -3063.6% vs KZR 0.0%) and valuation multiples (COCP N/M vs KZR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: COCP (1) vs KZR (6)
Institutional Metric COCP KZR Criterion Row Winner
Market Capitalization Scale $19.6M $54.4M Larger Scale KZR
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +26.9% +0.0% Higher Growth COCP
Operating Margin (TTM) Profitability -3063.6% 0.0% Higher Margin KZR
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -311.7% -59.9% Higher ROE KZR
52-Week Range Position Momentum 19% ($1โ€“$2) 94% ($4โ€“$8) Stronger Trend KZR
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 54% Vol 0.60ฮฒ ยท 8% Vol Lower Realized Risk KZR
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 60.1 / 100 (BUY) Higher Composite KZR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full COCP vs KZR Buy Guide
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KZR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live KZR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither COCP nor KZR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.